The leader

[Anonymous]

LLY 0.6% 0.1% -3.3% -0.3%
SPY 0.4% 9.2% 18.6% 3.1%
XLV -0.1% 2.6% 2.0% 1.9%
IRY 0.8% 1.7% 4.4% 3.0%
XPH 0.8% 2.2% 21.7% 2.0%
SSO 0.8% 19.9% 38.9% 6.0%
RWL 0.3% 10.9% 20.5% 3.6%
SDY 0.3% 2.7% 14.5% 1.2%
PRF 0.5% 10.6% 23.1% 3.1%
EPS 1.0% 8.5% 16.7% 3.6%

The "loss" leader!

 

[Anonymous]

Guidance

Analysts are looking for EPS of $1.09 on revenue of $5.99B. The consensus range is $1.07-$1.13 for EPS, and $5.74B-$6.27B for revenue, according to First Call. Positive catalysts for Q4 results may be seen coming from Japan and emerging markets. On the company's Q3 earnings conference call management said, Japan will be making "meaningful" contributions to results for the forseeable future. Drugs that may continue positive revenue momentum include Altimta, which was up 21% in Q3, and Humulin, up 75% in Q3. Zyprexa revenue was down 1% in Q3, and may be a lower for Q4 as well. Expiration losses should negatively impact margins this quarter but may be mitigated by tighter cost controls.

Source, SeekingAlpha